+250.1%
NXPI vs MRNA
+554.4%
-304.3%
-53.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.5% | +5.4% | -0.9% | +4.1% |
| 7D | +3.9% | -1.1% | +4.9% | +3.9% |
| 30D | +1.4% | +126.1% | -124.7% | -9.5% |
| 3M | -21.5% | +190.0% | -211.6% | -32.7% |
| 6M | +19.4% | +157.2% | -137.8% | +3.6% |
| YTD | +9.9% | +388.2% | -378.3% | -12.6% |
| 1Y | +7.9% | +467.0% | -459.1% | -16.2% |
| 3Y | +22.7% | +36.1% | -13.4% | +7.4% |
| 5Y | +22.1% | -68.0% | +90.0% | +12.6% |
| All | +250.1% | +554.4% | -304.3% | +214.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling